JP2014508720A5 - - Google Patents

Download PDF

Info

Publication number
JP2014508720A5
JP2014508720A5 JP2013543275A JP2013543275A JP2014508720A5 JP 2014508720 A5 JP2014508720 A5 JP 2014508720A5 JP 2013543275 A JP2013543275 A JP 2013543275A JP 2013543275 A JP2013543275 A JP 2013543275A JP 2014508720 A5 JP2014508720 A5 JP 2014508720A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
group
formula
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013543275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014508720A (ja
JP6076913B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/063533 external-priority patent/WO2012078633A2/en
Publication of JP2014508720A publication Critical patent/JP2014508720A/ja
Publication of JP2014508720A5 publication Critical patent/JP2014508720A5/ja
Application granted granted Critical
Publication of JP6076913B2 publication Critical patent/JP6076913B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013543275A 2010-12-07 2011-12-06 癌からの転移を阻害する方法 Expired - Fee Related JP6076913B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42064010P 2010-12-07 2010-12-07
US61/420,640 2010-12-07
PCT/US2011/063533 WO2012078633A2 (en) 2010-12-07 2011-12-06 Methods of inhibiting metastasis from cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017002396A Division JP2017122085A (ja) 2010-12-07 2017-01-11 癌からの転移を阻害する方法

Publications (3)

Publication Number Publication Date
JP2014508720A JP2014508720A (ja) 2014-04-10
JP2014508720A5 true JP2014508720A5 (https=) 2015-01-29
JP6076913B2 JP6076913B2 (ja) 2017-02-08

Family

ID=46162450

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013543275A Expired - Fee Related JP6076913B2 (ja) 2010-12-07 2011-12-06 癌からの転移を阻害する方法
JP2017002396A Pending JP2017122085A (ja) 2010-12-07 2017-01-11 癌からの転移を阻害する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017002396A Pending JP2017122085A (ja) 2010-12-07 2017-01-11 癌からの転移を阻害する方法

Country Status (4)

Country Link
US (4) US8435993B2 (https=)
EP (1) EP2648754A4 (https=)
JP (2) JP6076913B2 (https=)
WO (1) WO2012078633A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435993B2 (en) * 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer
US8883989B2 (en) * 2011-10-18 2014-11-11 Regents Of The University Of Minnesota Fractalkine binding polynucleotides and methods of use
PH12021553014A1 (en) * 2012-02-27 2022-09-05 Ablynx Nv Cx3cr1-binding polypeptides
EP3035970A1 (en) * 2013-08-21 2016-06-29 Boehringer Ingelheim International GmbH Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease
WO2016024096A1 (en) * 2014-08-11 2016-02-18 Redx Pharma Plc Antibacterial compounds
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
CA3008279A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017112894A1 (en) 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
EP3472129A4 (en) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
US11267817B2 (en) 2017-05-02 2022-03-08 Drexel University Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists
WO2019014122A1 (en) * 2017-07-08 2019-01-17 The Brigham And Women's Hospital, Inc. METHODS FOR ENHANCING ANTIANGIOGENIC THERAPY AND IMMUNOTHERAPY
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
MX2022000917A (es) 2019-07-23 2022-04-07 Univ Texas Agonistas de receptores de cx3cr1 bicíclicos.
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
IL298941A (en) 2020-06-11 2023-02-01 Chdi Foundation Inc Heterocyclic compounds and imaging agents for the imaging of huntingtin protein
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3939159A (en) * 1974-05-29 1976-02-17 American Hoechst Corporation Spiro(pyrrolo (1,2-A)quinoxalines)
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
ES2124303T3 (es) 1992-03-25 1999-02-01 Depomed Inc Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
DE4228095A1 (de) * 1992-08-24 1994-03-03 Asta Medica Ag Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
HK1050135A1 (zh) 1999-11-02 2003-06-13 Depomed, Inc. 用於促进将药物给予胃的饭後模式药理学诱导
DE60123384T2 (de) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
AU2000273378A1 (en) 2000-02-18 2001-08-27 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
AU2001247521A1 (en) 2000-03-16 2001-09-24 The Regents Of The University Of California Assay for agents that induce chemokinesis
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
MXPA03011096A (es) 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
AU2002357932A1 (en) 2001-12-18 2003-06-30 Whitehead Institute For Biomedical Research Fusion partner cells and uses thereof
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
WO2004045526A2 (en) 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
EP1675862A1 (en) 2003-10-07 2006-07-05 AstraZeneca AB New 2-substituted, 4-amino-thiazolo 4,5-d pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
US20060003020A1 (en) * 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
US20060115834A1 (en) * 2004-10-19 2006-06-01 University Of Iowa Research Foundation Methods of identifying metastatic potential in cancer
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
EP2069365A4 (en) 2006-09-29 2011-11-02 Astrazeneca Ab NOVEL [1, 3] THIAZOLO [4,5-D] PYRIMIDIN-2 (3H) -AMINE 5,7-DISUBSTITUTED DERIVATIVES AND THEIR USE IN THERAPY
AU2009291749B2 (en) * 2007-05-22 2015-05-21 Chemocentryx, Inc. 4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines
MY150602A (en) * 2007-08-31 2014-01-30 Purdue Pharma Lp Subtituted-quinoxaline-type piperidine compounds and the uses thereof
HRP20191953T8 (hr) * 2008-03-07 2021-06-25 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. DERIVATI 1-BENZIL-3-HIDROKSIMETILINDAZOLA I NJIHOVA UPORABA U LIJEČENJU BOLESTI KOJE SE BAZIRAJU NA EKSPRESIJI MCP-1, CX3CR1 i P40
AR071036A1 (es) 2008-03-26 2010-05-19 Astrazeneca Ab Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1.
ES2554513T3 (es) * 2008-05-23 2015-12-21 Novartis Ag Derivados de quinolinas y quinoxalinas como inhibidores de la proteína tirosina quinasa
JP2011127042A (ja) 2009-12-18 2011-06-30 Fujifilm Corp アゾ顔料、アゾ顔料の製造方法、アゾ顔料を含む分散物、及び着色組成物
US8785490B2 (en) * 2010-04-09 2014-07-22 University Of Louisville Research Foundation, Inc. Compounds for treating disease, for administering, and for pharmaceutical compositions
US8435993B2 (en) 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer

Similar Documents

Publication Publication Date Title
JP2014508720A5 (https=)
JP2023514872A5 (https=)
CA2640080A1 (en) Compositions and methods for the treatment of ophthalmic disease
JP2016516043A5 (https=)
RU2014105624A (ru) Соединения индазола, способ их применения и фармацевтическая композиция
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2020505356A5 (https=)
JP2019521988A5 (https=)
JP2010502751A5 (https=)
JP2004534774A5 (https=)
JP2013518129A5 (https=)
JP2009536620A5 (https=)
ATE450532T1 (de) Pyridinyl- oder pyrimidinylthiazole mit proteinkinasehemmender wirkung
JP2014528464A5 (https=)
JP2014500265A5 (https=)
JP2005517006A5 (https=)
JP2016510785A5 (https=)
JP2013523814A5 (https=)
JP2026020169A (ja) Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤
EP2455080A1 (en) S1P1 receptor agonists for use in the treatment of multiple sclerosis
JP2022535734A5 (https=)
JP2017501983A5 (https=)
JP2023162250A (ja) がんの治療のためのｎｏｘ阻害剤の使用
JP2010536821A5 (https=)
JP2022500428A5 (https=)